277 related articles for article (PubMed ID: 27694901)
1. MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.
Sochalska M; Schuler F; Weiss JG; Prchal-Murphy M; Sexl V; Villunger A
Oncogene; 2017 Apr; 36(15):2066-2073. PubMed ID: 27694901
[TBL] [Abstract][Full Text] [Related]
2. Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells.
Mensink M; Anstee NS; Robati M; Schenk RL; Herold MJ; Cory S; Vandenberg CJ
Cell Death Differ; 2018 Mar; 25(4):797-808. PubMed ID: 29339775
[TBL] [Abstract][Full Text] [Related]
3. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
[TBL] [Abstract][Full Text] [Related]
4. IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis.
Vecchio E; Golino G; Pisano A; Albano F; Falcone C; Ceglia S; Iaccino E; Mimmi S; Fiume G; Giurato G; Britti D; Scala G; Quinto I
Cell Death Dis; 2019 Apr; 10(4):320. PubMed ID: 30975981
[TBL] [Abstract][Full Text] [Related]
5. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.
Kelly PN; Grabow S; Delbridge AR; Strasser A; Adams JM
Blood; 2011 Dec; 118(24):6380-6. PubMed ID: 21998213
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of Vav-promoter-driven overexpression of BCLX and BFL1 on lymphocyte survival and B cell lymphomagenesis.
Tuzlak S; Haschka MD; Mokina AM; Rülicke T; Cory S; Labi V; Villunger A
FEBS J; 2018 Apr; 285(8):1403-1418. PubMed ID: 29498802
[TBL] [Abstract][Full Text] [Related]
7. Critical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis.
Grabow S; Kelly GL; Delbridge AR; Kelly PN; Bouillet P; Adams JM; Strasser A
Cell Death Dis; 2016 Mar; 7(3):e2132. PubMed ID: 26962682
[TBL] [Abstract][Full Text] [Related]
8. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
9. Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma.
Kelly PN; Puthalakath H; Adams JM; Strasser A
Blood; 2007 Jun; 109(11):4907-13. PubMed ID: 17317859
[TBL] [Abstract][Full Text] [Related]
10. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
11. IL-6 promotes MYC-induced B cell lymphomagenesis independent of STAT3.
Petrenko O; Li J; Cimica V; Mena-Taboada P; Shin HY; D'Amico S; Reich NC
PLoS One; 2021; 16(3):e0247394. PubMed ID: 33651821
[TBL] [Abstract][Full Text] [Related]
12. Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes.
Zörnig M; Busch G; Beneke R; Gulbins E; Lang F; Ma A; Korsmeyer S; Möröy T
Oncogene; 1995 Nov; 11(10):2165-74. PubMed ID: 7478538
[TBL] [Abstract][Full Text] [Related]
13. The novel double-hit, t(8;22)(q24;q11)/MYC-IGL and t(14;15)(q32;q24)/IGH-BCL2A1, in diffuse large B-cell lymphoma.
Akasaka T; Kishimori C; Fukutsuka K; Nakagawa M; Takeoka K; Hayashida M; Honjo G; Ohno H
Cancer Genet; 2017 Aug; 214-215():26-31. PubMed ID: 28595732
[TBL] [Abstract][Full Text] [Related]
14. Conditional knockdown of BCL2A1 reveals rate-limiting roles in BCR-dependent B-cell survival.
Sochalska M; Ottina E; Tuzlak S; Herzog S; Herold M; Villunger A
Cell Death Differ; 2016 Apr; 23(4):628-39. PubMed ID: 26450454
[TBL] [Abstract][Full Text] [Related]
15. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis.
Nilsson LM; Keller UB; Yang C; Nilsson JA; Cleveland JL; Roussel MF
Oncogene; 2007 May; 26(20):2833-9. PubMed ID: 17099725
[TBL] [Abstract][Full Text] [Related]
16. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
17. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
[TBL] [Abstract][Full Text] [Related]
18. BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia.
Li Y; Deutzmann A; Choi PS; Fan AC; Felsher DW
Oncotarget; 2016 May; 7(19):26926-34. PubMed ID: 27095570
[TBL] [Abstract][Full Text] [Related]
19. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
20. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]